Cassava Sciences, Inc.(SAVA)Earnings, Financials & Key Ratios
SAVA•NASDAQ
$1.32
Price updated Jun 20, 2026
AboutCassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Show more
- Revenue$0
- EBITDA-$140M-34.4%
- Net Income-$24M+75.0%
- EPS (Diluted)-0.52+77.6%
- ROE-17.19%+67.7%
SAVA Price & Volume
Cassava Sciences, Inc. (SAVA) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Challenges Clinical Development Outlook
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial binary outcome
Key Thesis Takeaways
- Cassava Sciences remains a high-risk, pre-revenue biotechnology firm entirely dependent on the successful clinical validation of its lead candidate, Simufilam.
- The company faces significant financial pressure as it navigates late-stage trials, evidenced by a cumulative retained earnings deficit of -$483.5 million and ongoing operational losses.
- Investors must weigh the binary outcome of clinical milestones against the firm's narrowing liquidity buffer and the potential for future dilutive capital raises to sustain operations.
Verdict Logic
the firm's reliance on external financing is underscored by a 2025Q3 net loss of $10.8 million and a lack of revenue-generating activities, creating substantial risk for equity holders.
SAVA Growth Metrics
Cassava Sciences, Inc. (SAVA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-500.27%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-58.7%
Return on Capital
10 Years-47.81%
5 Years-44.26%
3 Years-63.7%
Last Year-99.87%
SAVA Recent Earnings
Cassava Sciences, Inc. (SAVA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (50%)
Q4 2025Latest
Nov 12, 2025Metric
Actual
Est
EPS
$0.22+18.5%
$0.27
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.18
—
Rev
—
—
Q2 2025
May 8, 2025Metric
Actual
Est
EPS
$0.48
—
Rev
—
—
Q2 2025
Mar 3, 2025Metric
Actual
Est
EPS
$0.57+16.2%
$0.68
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 12, 2025 | $0.22vs $0.27+18.5% | — |
| Q3 2025 | Aug 14, 2025 | $0.18 | — |
| Q2 2025 | May 8, 2025 | $0.48 | — |
| Q2 2025 | Mar 3, 2025 | $0.57vs $0.68+16.2% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Cassava Sciences, Inc. (SAVA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.32 | $63.77M | -2.54 | — | — | -17.19% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $1.03 | $32.32M | -0.95 | — | -26078.89% | -218.67% | — | |
| $2.71 | $251.14M | -5.02 | — | — | -38.76% | — | |
| $2.54 | $258.5M | -2.93 | -86.92% | -1971.7% | -101.76% | — |
Compare SAVA vs Peers
Cassava Sciences, Inc. (SAVA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when SAVA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SAVA Frequently Asked Questions
Cassava Sciences, Inc. (SAVA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is SAVA profitable?
Cassava Sciences, Inc. (SAVA) reported a net loss of $106.0M for fiscal year 2024.
Dividend & Returns
What is SAVA's return on equity?
Cassava Sciences, Inc. (SAVA) has a return on equity (ROE) of -17.2%. Negative ROE indicates the company is unprofitable.
What is Cassava Sciences, Inc.'s free cash flow?
Cassava Sciences, Inc. (SAVA) had negative free cash flow of $83.9M in fiscal year 2024, likely due to heavy capital investments.